MedTrace Logo

Study to Evaluate the Effect of Pasteurized Akkermansia Muciniphila (pAkk) on Complaints Related to IBS

NCT05348642 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-03-02

No results posted yet for this study

Summary

Double-blind, randomised, placebo-controlled study to evaluate the benefit of pasteurized Akkermansia muciniphila in reducing complaints related to irritable bowel syndrome.

Further objectives are to evaluate the beneficial potential of pAkk on any anxiety and depression complaints, as well as its safety and tolerability.

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

pasteurized A. muciniphila

pasteurized A. muciniphila - oral daily dose

DIETARY_SUPPLEMENT

placebo

Placebo = identical to verum regarding the form, size, taste, color and intake

Sponsors & Collaborators

  • A-Mansia Biotech S.A.

    lead INDUSTRY

Principal Investigators

  • Study Director · A-Mansia Biotech

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-21
Primary Completion
2023-01-06
Completion
2023-01-06

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05348642 on ClinicalTrials.gov